Regeneron Pharmaceuticals Inc. (REGN)

Index:

Nasdaq 100

$ 490.28
   
  • Change Today:
    $-115.11
  • 52 Week High: $1,201.76
  • 52 Week Low: $485.00
  • Currency: US Dollars
  • Shares Issued: 107.80m
  • Volume: 6,313,059
  • Market Cap: $52,852m
  • RiskGrade: 129

Regeneron Pharmaceuticals Covid-19 antibodies 100% effective in blocking infections

By Alexander Bueso

Date: Tuesday 26 Jan 2021

LONDON (ShareCast) - (Sharecast News) - Regeneron Pharmaceuticals antibody cocktail severely curtails Covid-19 symptoms and infections, the results of a late-stage trial showed.

The trial involving 400 patients with at least one household member sick from Covid-19 showed that the two-antibody cocktail, known as REGEN-COV, completely cut symptomatic infections of the novel coronavirus.

Overall rates of infections meanwhile were reduced by approximately half.

A rival treatment from Eli Lilly, bamlanivimab, had shown a similar efficacy the week before, reducing Covid-19 infections among nursing home resident in a trial by 80%.

As of 1650 GMT, Regeneron shares had slipped 1.11% to $542.14.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

REGN Market Data

Currency US Dollars
Share Price $ 490.28
Change Today $ -115.11
% Change -19.01 %
52 Week High $1,201.76
52 Week Low $485.00
Volume 6,313,059
Shares Issued 107.80m
Market Cap $52,852m
RiskGrade 129

What The Brokers Say

Strong Buy 10
Buy 10
Neutral 5
Sell 1
Strong Sell 0
Total 26
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 30-May-2025

Time Volume / Share Price
16:00 1,330 @ $489.52
15:59 100 @ $490.11
15:59 400 @ $490.10
15:59 540 @ $490.10
15:59 118 @ $489.95

Top of Page